Journal of Prevention and Treatment for Stomatological Diseases ›› 2020, Vol. 28 ›› Issue (4): 267-272.doi: 10.12016/j.issn.2096-1456.2020.04.012

• Review Articles • Previous Articles    

Application progress of recombinant human endostatin in the treatment of head and neck cancer

LI Xiaodong,MENG Jian()   

  1. Stomatology, Xuzhou Central Hospital, Xuzhou 221000, China
  • Received:2019-01-03 Revised:2019-06-24 Online:2020-04-20 Published:2020-03-31
  • Contact: Jian MENG E-mail:mrocket@126.com

RichHTML

5

PDF (PC)

22

Abstract:

The main treatment of head and neck cancer is comprehensive sequential treatment, but the 5-year overall survival rate is less than 50%. Strategies to further improve the curative effect of head and neck cancer are urgently needed in the clinic. Recombinant human vascular endostatin is an antiangiogenesis drug targeting vascular endothelial cells, which has a certain inhibitory effect on tumors. The treatment of malignant tumors by drugs alone is not significantly better than chemoradiation, but combined with radiotherapy and chemotherapy, it can increase the effect of radiotherapy and chemotherapy without drug resistance by changing the distribution of blood vessels, reducing oxygen and normalizing blood vessels. Head and neck tumor treatment has certain advantages. New tumor treatments are expected. The results of a literature review showed that the mechanism of action of recombinant human endostatin mainly includes regulating the matrix protein inside and outside the endothelial cells to influence neovascularization, acting on receptors related to the surface of endothelial cells, reversing abnormal neovascularization to achieve vascular normalization, inhibiting hypoxia inducible factor to improve the hypoxic status of the tumor area, and regulating the cell cycle to ensure the tumor cells are sensitive to radiation in the sensitive period, and vascular normalization can increase the effect of radiotherapy. This treatment has a good synergistic effect with radiotherapy and chemotherapy of head and neck tumors and has a good effect on advanced head and neck tumors.

Key words: recombinant human endostatin, head and neck cancer, vascular normalization, vascular endothelium, targeted drug, targeted therapy, biotherapy, chemotherapy synergy, radiosensitive phase

CLC Number: 

  • R78
[1] O′Reilly MS, Boehm T, Shing Y , et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997,88(2):277-285.
[2] Mohajeri A, Sanaei S, Kiafar F , et al. The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering[J]. Adv Pharm Bull, 2017,7(1):21-34.
[3] Zhou S, Zuo L, He X , et al. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: a retrospective comparison with standard chemotherapy[J]. Thorac Cancer, 2018,9(11):1354-1360.
[4] Qin RS, Zhang ZH, Zhu NP , et al. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma[J]. BMC Cancer, 2018,18(1):967.
[5] 刘书昊, 潘运龙, 覃莉 , 等. 纳米金结合重组人血管内皮抑素对人脐静脉内皮细胞增殖、凋亡及迁移的影响[J]. 中华实验外科杂志, 2018,35(4):645-648.
Liu SH, Pan YL, Qin L , et al. The effect of the gold nanoparticles combined with endostar on proliferation, apoptosis, migration of human umbilical vein endothelial cells[J]. Chin J Exp Surg, 2018,35(4):645-648.
[6] Nemoto T, Kubota S . Vascular endothelial cadherin is an endostatin receptor[J]. Biologia (Bratislava), 2011,66(4):721-726.
[7] Xu X, Mao W, Chen Q , et al. Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway[J]. PLoS One, 2014,9(9):e107463.
[8] Zhang Q, Cao J, Xue K , et al. Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma[J]. Onco Targets Ther, 2016,10:145-151.
[9] Xiao L, Yang S, Hao J , et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis[J]. Cancer Lett, 2015,359(1):148-154.
[10] Ning T, Jiang M, Peng Q , et al. Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model[J]. Thorac Cancer, 2012,3(3):229-238.
[11] Fu W, Zhuo J, Hu L . Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer[J]. Oncol Lett, 2017,13(1):196-200.
[12] Yu M, Han Y, Zhuo H , et al. Endostar, a modified endostatin induces vascular normalization to improve chemotherapy efficacy through suppression of src signaling pathway[J]. Cancer Biother Radiopharm, 2018,33(4):131-138.
[13] Li W, Zhao X, Du B , et al. Gold nanoparticle-mediated targeted delivery of recombinant human endostatin normalizes tumour vasculature and improves cancer therapy[J]. Sci Rep, 2016,6:30619.
[14] Jin T, Li B, Chen XZ . A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286)[J]. Oncol Res, 2013,21(6):317-323.
[15] Jin T, Jiang F, Jin QF , et al. Endostar combined with gemcitabine and cisplatin chemotherapy for patients with metastatic nasopharyngeal carcinoma: an update[J]. Transl Oncol, 2018,11(2):286-291.
[16] Chen J, Yao Q, Huang M , et al. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01)[J]. Int J Cancer, 2018,142(10):2130-2138.
[17] Chen C, Liu SR, Zhou S , et al. Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: three case reports[J]. Medicine (Baltimore). 2019,98(32):e16592.
[18] Lu S, Li L, Luo Y , et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer[J]. J Thorac Oncol, 2015,10(1):206-211.
[19] Chen J, Qi J, Yu B , et al. A retrospective study to compare five induction chemotherapy regimens prior to radiotherapy in the reduction of regional lymph node size in patients with nasopharyngeal carcinoma[J]. Med Sci Monit, 2018,24:2562-2568.
[20] Zhang K, Wang Y, Yu X , et al. Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth[J]. BMC Cancer, 2017,17(1):899.
[21] Liu GF, Chang H, Li BT , et al. Effect of recombinant human endostatin onradiotherapy for esophagus cancer[J]. Asian Pac J Trop Med, 2016,9(1):86-90.
[22] Zheng YF, Ge W, Xu HL , et al. Endostar enhances the antitumor effects of radiation by affecting energy metabolism and alleviating the tumor microenvironment in a Lewis lung carcinoma mouse model[J]. Oncol Lett, 2015,10(5):3067-3072.
[23] Zhang L, Ge W, Hu K , et al. Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells[J]. Mol Biol Rep, 2012,39(1):89-95.
[24] He L, Zhao C, Li Y , et al. Antiangiogenic effects of recombinant human endostatin in lung cancers[J]. Mol Med Rep, 2018,17(1):79-86.
[25] 何朗, 刘康, 陈梅 , 等. 重组人血管内皮抑素联合顺铂不同时相治疗小鼠Lewis肺癌移植瘤疗效观察[J]. 中华肿瘤防治杂志, 2018,25(20):1422-1428.
He L, Liu K, Chen M , et al. Effect of recombinant human endostatin combined with cisplatin on different stages of Lewis lung cancer xenograft in mice[J]. Chin J Cancer Prev Treat, 2018,25(20):1422-1428.
[26] Chen X, Zhang H, Zhu H , et al. Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer[J]. Tumour Biol, 2016,37(4):4679-4688.
[27] Zhu H, Yang X, Ding Y , et al. Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia[J]. Sci Rep, 2015,5:14503.
[28] Kareemaghay S, Tavassoli M . Clinical immunotherapeutic approaches for the treatment of head and neck cancer[J]. Int J Oral Maxillofac Surg, 2019,48(4):419-436.
[29] Ye W, Liu R, Pan C , et al. Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma[J]. Mol Ther, 2014,22(6):1221-1229.
[30] Kang M, Wang F, Liao X , et al. Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma[J]. Medicine (Baltimore), 2018,97(25):e11118.
[31] Mardani M, Andishe TA, Ranjbar MA , et al. Serum endostatin levels in oral squamous cell carcinoma[J]. Iran J Otorhinolaryngol, 2018,30(98):125-130.
[32] Alahuhta I, Aikio M, Vayrynen O , et al. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment[J]. Exp Cell Res, 2015,336(1):130-140.
[33] Li Y, Jin F, Wu W , et al. Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma[J]. Zhonghua Zhong Liu Za Zhi, 2015,37(2):128-132.
[34] Cheng Y, Nie L, Liu Y , et al. Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer[J]. Thorac Cancer, 2019,10(7):1576-1580.
[35] Folkman J . Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action[J]. Exp Cell Res, 2006,312(5):594-607.
[36] Chen Z, Luo Q, Zhou Z , et al. Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression[J]. Oncotarget, 2017,8(45):79703-79711.
[37] Yan M, Dongmei B, Jingjing Z , et al. Antitumor activities of liver-targeting peptide modified recombinant human endostatin in BALB/c-nu mice with hepatocellular carcinoma[J]. Sci Rep, 2017,7(1):14074.
[38] Xing S, Fan Z, Shi L , et al. Successful treatment of brain radiation necrosis resulting from triple-negative breast cancer with Endostar and short-term hyperbaric oxygen therapy: a case report[J]. Onco Targets Ther, 2019,12:2729-2735.
[39] Li BL, Hu XL, Zhao XH , et al. Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: a clinical study[J]. J Chemother, 2015,27(5):301-306.
[1] JI Tong. Diagnosis and treatment of head and neck osteosarcoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(9): 545-550.
[2] GUO Xiao,DU Xinmei,CHENG Lei,ZHOU Xuedong,LI Mingyun. Research progress on the function and metabolism of d-alanine in bacteria [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(4): 264-267.
[3] Chaobin PAN. Research progress in comprehensive and sequential treatment of tongue squamous cell carcinoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(5): 273-280.
[4] WANG Xing,MENG Jian. Clinical effect of iodine 125 seeds implantation combined with EGFR inhibitor for advanced squamous cell carcinoma in tongue base [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2016, 24(11): 671-673.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Chao TANG,Jing SUN,Ju-feng CHEN. Influence of nursing intervention on the life quality of patients with tongue cancer after operation[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2016, 24(3): 177 -179 .
[2] Hong-chang LAI,Jun-yu SHI. Maxillary sinus floor elevation[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(1): 8 -12 .
[3] WANG An-xun. Research progress on the invasion and metastasis of tongue squamous cell carcinoma[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2016, 24(5): 261 -266 .
[4] Pin ZHOU, Yang-fei LI. MRI study of temporomandibular joint disc position in asymptomatic volunteers[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(4): 239 -244 .
[5] Xinxin XIA, Fang FANG, Lijuan CHENG. Shaping ability of Pathfile and WaveOne in simulated root canals[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(6): 365 -368 .
[6] Yuanhong LI, Xinyi FANG, Yu QIU, Lei CHENG. Experimental study on the effects of green tea on salivary flow rate and pH value[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(9): 560 -564 .
[7] Chengzhang LI. Masticatory muscles in occlusion[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(12): 755 -760 .
[8] . [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(1): 1 .
[9] Zhirong WU, Shiguang Huang. Research progress on the etiology, clinical examination and treatment of peri-implantitis[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(6): 401 -405 .
[10] Xiaowu YAO, Shisheng CHEN, Zizheng LU, Minxiao LIN. Clinical report and literature review on the amyloidosis of salivary glands[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(8): 533 -536 .

Copyright © Editorial Board of Journal of Prevention and Treatment for Stomatological Diseases

This work is licensed under a Creative Commons Attribution 3.0 License.

Address:Guangzhou City Jiangnan Road South 366, Editorial office ofJournal of Prevention and Treatment for Stomatological Diseases, zip code: 510280　Fax:020-34304115　E-mail：kqjbfz@vip.126.com

Supported by:Beijing Magtech

This work is licensed under a Creative Commons Attribution 3.0 License.